Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. demonstrates a robust growth outlook driven by its ability to cross-sell new services and expand risk-based product offerings, with the potential for the Aetna contract to generate over $2 billion in annual revenue. The company maintains a strong pipeline valued at $650 million, showcasing the highest momentum in its history, alongside consistent top-line growth that has exceeded its mid-teens revenue growth target. Additionally, the increasing prevalence of disease, particularly within specialty care areas such as oncology and cardiology, combined with favorable trends pushing towards value-based payment models, positions Evolent to capitalize on a substantial total addressable market and sustain demand for its innovative solutions.

Bears say

Evolent Health Inc faces a significant revenue decline as the company's non-enhanced revenue is projected to fall from approximately $285 million in 2025 to around $170 million in 2026 due to a shift in revenue mix. Additionally, management anticipates headwinds from a potential 65% decline in Health Insurance Exchange (HIX) membership and a 3% decrease in Medicare Advantage contracts, leading to an adjusted EBITDA forecast between $134 million and $144 million, which includes anticipated benefits from AI initiatives. These factors, combined with predictions of a 5% decline in Medicaid membership potentially dragging EBITDA down by $8 million to $10 million, contribute to a negative outlook on Evolent Health's stock.

Evolent Health (EVH) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 15 analysts, Evolent Health (EVH) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.